Portal de Periódicos da CAPES

Aldosterone antagonists for preventing the progression of chronic kidney disease

2008; Cochrane; Linguagem: Inglês

10.1002/14651858.cd007004

1469-493X

Sankar D. Navaneethan, Sagar U Nigwekar, Giovanni FM Strippoli,

Blood Pressure and Hypertension Studies

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess: The effects of aldosterone antagonists (both selective and non‐selective) on renal function (such as 24 hour albuminuria, proteinuria, glomerular filtration rate, serum creatinine, need for renal replacement therapy etc) in both nephrotic and non‐nephrotic range proteinuric patients when used alone and in patients who were already on ACEi alone, ARB alone or both. The effects of aldosterone antagonists (both selective and non‐selective) on patient centred end points such as incidence of cardiovascular events, hospitalizations and all‐cause mortality rates when used alone or in patients who were already on ACEi alone, ARB alone or both. Adverse effects of aldosterone antagonists (both selective and non‐selective) such as hyperkalaemia and gynaecomastia when used alone or in patients who were already on ACEi alone, ARB alone or both.